CEL-SCI (CVM) Stock Forecast, Price & News

CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions

Are investors shorting CEL-SCI?

CEL-SCI saw a increase in short interest in April. As of April 30th, there was short interest totaling 9,420,000 shares, an increase of 27.6% from the April 15th total of 7,380,000 shares. Based on an average daily trading volume, of 1,770,000 shares, the days-to-cover ratio is presently 5.3 days.
View CEL-SCI's Short Interest.

When is CEL-SCI's next earnings date?

CEL-SCI is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for CEL-SCI.

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSEAMERICAN:CVM) released its earnings results on Monday, May, 16th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by $0.07.
View CEL-SCI's earnings history.

When did CEL-SCI's stock split? How did CEL-SCI's stock split work?

CEL-SCI shares reverse split on Thursday, June 15th 2017. The 1-25 reverse split was announced on Monday, June 12th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 14th 2017. An investor that had 100 shares of CEL-SCI stock prior to the reverse split would have 4 shares after the split.

Who are CEL-SCI's key executives?

CEL-SCI's management team includes the following people:

• Mr. Geert R. Kersten, CEO, Principal Accounting & Financial Officer, Treasurer and Director (Age 63, Pay $675.65k)
• Ms. Patricia B. Prichep, Sr. VP of Operations & Corp. Sec. (Age 71, Pay $270.05k)
• Dr. Eyal Talor Ph.D., Chief Scientific Officer (Age 66, Pay $320.86k)
• Dr. Daniel H. Zimmerman Ph.D., Sr. VP of Research & Cellular Immunology (Age 81, Pay $249.01k)
• Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 80, Pay $225.36k)

Who are some of CEL-SCI's key competitors?

Some companies that are related to CEL-SCI include Century Therapeutics (IPSC), Inhibrx (INBX), Cullinan Oncology (CGEM), Aura Biosciences (AURA), Atara Biotherapeutics (ATRA), Mesoblast (MESO), Humacyte (HUMA), Immunovant (IMVT), Ocugen (OCGN), Agenus (AGEN), ADMA Biologics (ADMA), Vaxart (VXRT), Immatics (IMTX), Monte Rosa Therapeutics (GLUE) and MeiraGTx (MGTX).
View all of CVM's competitors.

What other stocks do shareholders of CEL-SCI own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CEL-SCI investors own include Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Savara (SVRA), Molecular Templates (MTEM), Gilead Sciences (GILD), Heat Biologics (HTBX), Idera Pharmaceuticals (IDRA), VBI Vaccines (VBIV) and CymaBay Therapeutics (CBAY).

What is CEL-SCI's stock symbol?

CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."

Who are CEL-SCI's major shareholders?

CEL-SCI's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.63%), Vanguard Group Inc. (4.78%), State Street Corp (2.27%), Renaissance Technologies LLC (1.79%), D.A. Davidson & CO. (0.99%) and Northern Trust Corp (0.81%). Company insiders that own CEL-SCI stock include Eyal Talor, Geert R Kersten, John Cipriano, Peter R Young and Robert Eugene Watson.
View institutional ownership trends for CEL-SCI.

Which institutional investors are selling CEL-SCI stock?

CVM stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Simplex Trading LLC, Walleye Trading LLC, GSA Capital Partners LLP, BlackRock Inc., Qube Research & Technologies Ltd, Group One Trading L.P., and Virtu Financial LLC.
View insider buying and selling activity for CEL-SCI or view top insider-selling stocks.

Which institutional investors are buying CEL-SCI stock?

CVM stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Goldman Sachs Group Inc., Walleye Capital LLC, Advisor Group Holdings Inc., Dimensional Fund Advisors LP, D.A. Davidson & CO., Cutter & CO Brokerage Inc., and Allspring Global Investments Holdings LLC. Company insiders that have bought CEL-SCI stock in the last two years include Geert R Kersten, Peter R Young, and Robert Eugene Watson.
View insider buying and selling activity for CEL-SCI or or view top insider-buying stocks.

How do I buy shares of CEL-SCI?

Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CEL-SCI's stock price today?

One share of CVM stock can currently be purchased for approximately $3.06.

How much money does CEL-SCI make?

CEL-SCI has a market capitalization of $132.42 million and generates $560 thousand in revenue each year. The company earns $-36.36 million in net income (profit) each year or ($0.930010) on an earnings per share basis.

How many employees does CEL-SCI have?

CEL-SCI employs 2,020 workers across the globe.

What is CEL-SCI's official website?

The official website for CEL-SCI is www.cel-sci.com.

How can I contact CEL-SCI?

CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at (703) 506-9460, via email at [email protected], or via fax at 703-506-9471.